(20S)-Protopanaxatriol (Synonyms: 20(S)-APPT, 20(S)-PPT) |
| Katalog-Nr.GC34965 |
Ein aktiver Ginsenosid-Metabolit
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 34080-08-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
(20S)-Protopanaxatriol is a metabolite derived from ginsenosides, possessing diverse biological activities and pharmacological effects[1]. (20S)-Protopanaxatriol functions by binding to glucocorticoid receptors and estrogen receptors, and can inhibit the activity of liver X receptor alpha[2]. (20S)-Protopanaxatriol is capable of modulating cellular glycolysis levels[3], and exhibits significant anti-cancer properties by effectively suppressing cancer progression[4].
In vitro, treatment of triple-negative breast cancer cell lines SUM-159-PT and MDA-MB-231 with (20S)-Protopanaxatriol (20-60μM) for 24-48 hours significantly inhibited cell proliferation and migration, while inducing non-protective autophagy and apoptosis[5]. When differentiating 3T3-L1 preadipocytes were treated with (20S)-Protopanaxatriol (10μM) for 7 days, (20S)-Protopanaxatriol markedly promoted adipocyte differentiation and lipid accumulation, concurrently activating the transcriptional activity of peroxisome proliferator-activated receptor gamma[6].
In vivo, oral administration of (20S)-Protopanaxatriol (10mg/kg and 20mg/kg) once daily for three consecutive days in TNBS-induced colitis mice significantly suppressed colon shortening and myeloperoxidase activity, while reducing the expression of pro-inflammatory cytokines[7]. In tumor-bearing mice inoculated with H1975-luc cells, daily intraperitoneal injection of (20S)-Protopanaxatriol (1mg/kg/day) in combination with Gefitinib (50mg/kg/day) resulted in significant inhibition of tumor growth and reversal of EGFR-TKI resistance[8].
References:
[1] Sun H, Ye Y, Pan Y. Immunological-adjuvant saponins from the roots of Panax notoginseng. Chem Biodivers. 2005 Apr;2(4):510-5.
[2] Oh GS, Yoon J, Lee GG, et al. 20(S)-protopanaxatriol inhibits liver X receptor α-mediated expression of lipogenic genes in hepatocytes. J Pharmacol Sci. 2015 Jun;128(2):71-7.
[3] Li J, Liu T, Zhao L, et al. Ginsenoside 20(S)‑Rg3 inhibits the Warburg effect through STAT3 pathways in ovarian cancer cells. Int J Oncol. 2015 Feb;46(2):775-81.
[4] Saw CL, Yang AY, Cheng DC, et al. Pharmacodynamics of ginsenosides: antioxidant activities, activation of Nrf2, and potential synergistic effects of combinations. Chem Res Toxicol. 2012 Aug 20;25(8):1574-80.
[5] Li Y, Wang P, Zou Z, et al. Ginsenoside (20S)-protopanaxatriol induces non-protective autophagy and apoptosis by inhibiting Akt/mTOR signaling pathway in triple-negative breast cancer cells. Biochem Biophys Res Commun. 2021 Dec 17;583:184-191.
[6] Liu Y, Guo X, Wu L, et al. Lipid rafts promote liver cancer cell proliferation and migration by up-regulation of TLR7 expression. Oncotarget. 2016 Sep 27;7(39):63856-63869.
[7] Lee SY, Jeong JJ, Eun SH, et al. Anti-inflammatory effects of ginsenoside Rg1 and its metabolites ginsenoside Rh1 and 20(S)-protopanaxatriol in mice with TNBS-induced colitis. Eur J Pharmacol. 2015 Sep 5;762:333-43.
[8] Huang Q, Wang Q, Li D, et al. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer. J Exp Clin Cancer Res. 2019 Mar 15;38(1):129.
| Cell experiment [1]: | |
Cell lines | SUM-159-PT and MDA-MB-231 cells (human triple-negative breast cancer cell lines) |
Preparation Method | TNBC cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) at 37°C, 5% CO₂. Cells were treated with (20S)-Protopanaxatriol at concentrations of 20-60µM for 24 hours. |
Reaction Conditions | 20-60μM; 24h |
Applications | (20S)-Protopanaxatriol significantly inhibited cell viability and clonogenic capacity in a dose-dependent manner, with an IC₅₀ of 60µM. (20S)-Protopanaxatriol also markedly suppressed cell migration ability. |
| Animal experiment [2]: | |
Animal models | Female nude mice bearing MDA-MB-231 xenograft tumors |
Preparation Method | Mice were intragastrically administered (20S)-Protopanaxatriol at 20mg/kg once every other day for a total of 7 times over 14 consecutive days. Tumor volume and weight were measured, and tissues were collected for histological analysis. |
Dosage form | 20mg/kg; i.g. |
Applications | (20S)-Protopanaxatriol significantly inhibited tumor growth and reduced tumor volume and weight compared to the control group. Histological examination showed no significant cytotoxic effects on major organs. |
References: | |
| Cas No. | 34080-08-5 | SDF | |
| Überlieferungen | 20(S)-APPT, 20(S)-PPT | ||
| Canonical SMILES | C[C@]([C@@](C[C@H]1O)([H])[C@]2(CC[C@@H]3O)C)(C[C@H](O)[C@@]2([H])C3(C)C)[C@]4([C@@]1([H])[C@]([C@@](C)(O)CC/C=C(C)/C)([H])CC4)C | ||
| Formula | C30H52O4 | M.Wt | 476.73 |
| Löslichkeit | DMSO: 100 mg/mL (209.76 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0976 mL | 10.4881 mL | 20.9762 mL |
| 5 mM | 419.5 μL | 2.0976 mL | 4.1952 mL |
| 10 mM | 209.8 μL | 1.0488 mL | 2.0976 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *